Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes
| Autor: | Baldev M Singh, Harit Buch, V. Baskar, D. Kamalakannan, D. M. Barton, C. Akarca |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Gastroenterology Body Mass Index Diabetes Complications Rosiglitazone Endocrinology Diabetes mellitus Internal medicine Internal Medicine medicine Edema Humans Hypoglycemic Agents Insulin Obesity Aged Glycated Hemoglobin business.industry Body Weight Middle Aged medicine.disease Thiazoles Diabetes Mellitus Type 2 Drug Therapy Combination Female Thiazolidinediones Median body medicine.symptom business Weight gain Body mass index medicine.drug |
| Zdroj: | Diabetic Medicine. 19:572-574 |
| ISSN: | 1464-5491 0742-3071 |
| DOI: | 10.1046/j.1464-5491.2002.00734.x |
| Popis: | Aims To evaluate the influence of addition of rosiglitazone to insulin therapy over a 24-week period in massively obese patients with poorly controlled Type 2 diabetes taking large doses of insulin. Methods Eight massively obese patients (median body mass index (BMI) 42 kg/m2) with Type 2 diabetes who were on large doses of insulin (median daily dose of 204 U) and/or had poor glycaemic control (median HbA1c of 8.1% (upper limit for normal 5.5%)) were treated over a 24-week period with the combination of insulin and maximum doses of rosiglitazone. Outcomes monitored were changes in weight, BMI, HbA1c, dose of insulin and development of side-effects. Results At the end of 24 weeks there was a median weight gain of 3 kg (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text